Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
Amiloride HCI Tablets, USP 5 mg
Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.
CHMP recommends granting a marketing authorization for Santhera's Raxone® for the treatment of Leber's Hereditary Optic Neuropathy (LHON)
Pathogenesis of multiple sclerosis via environmental and genetic dysregulation of N-glycosylation.
Ocrelizumab in multiple sclerosis: risks and benefits.
No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
Mapi Pharma granted United States patent covering glatiramer depot for multiple sclerosis
Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
Slowing of brain atrophy and reductions in new multiple sclerosis lesions sustained at three years in patients treated with Genzyme's LemtradaTM
Abnormalities of Motor Imagery and Relationship With Depressive Symptoms in Mildly Disabling Relapsing-Remitting Multiple Sclerosis.
Diagnosis of exclusion: a case report of probable glatiramer acetate-induced eosinophilic myocarditis.
Protective Associations of HDL with Blood Brain Barrier Injury in Multiple Sclerosis Patients.
Effect of High-Dose Intravenous Methyl-prednisolone Treatment on Intraocular Pressure in Multiple Sclerosis Patients with Relapse.
Review of MR elastography applications and recent developments.
Multiple sclerosis remission following antiretroviral therapy in an HIV-infected man.
A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
Effects of Panax ginseng in Neurodegenerative Diseases.
Teva and Takeda announce agreement for glatiramer acetate for multiple sclerosis treatment in Japan
Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.
Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis.
Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
Pages
« first
‹ previous
…
154
155
156
157
158
159
160
161
162
…
next ›
last »